Clinical observation of nonvalvular atrial fibrillation through anticoagulant therapy L

Objective To explore the clinical effect and drug selection of nonvalvular atrial fibrillation (NVAF) by anticoagulation. Methods To analysis retrospectively the 96 NVAF patients with medical treatment in five years. The patients of warfarin group (n=32) took orally warfarin. The range of dosage was 1.25~5 mg/day and kept the INR between 2and 3. The patients of Tongxinluo capsule in combination with aspirin group (n=32) took orally Tongxinluo capsule (0.78 g,3 times a day) and aspirin (100 mg/d);Patients of aspirin group (n=32) took orally aspirin (100 mg/day). To observing and comparing the complication incidence of cerebral thromboembolism, hemorrhage etc, following up 2 years. Results The incidence of cerebral thromboembolism between warfarin group (3.33%/year) and Tongxinluo capsule combined with aspirin group (5.0%/year) had no remarkably significance (P>0.05).The result between aspirin group (17.2%/year) and Tongxinluo capsule combined with aspirin group had significance (P<0.05). The warfarin group between aspirin group had dramaticlly significance(P<0.01).The incidence of hemorrhage in warfarin group was 1.67%/year(n=1) and it was zero in the other two groups. Conclusion The effect of Tongxinluo capsule in combination with aspirin to prevent cerebral thromboembolism due to NVAF is same to that of warfarin and significantly better than that of aspirin.Tongxinluo capsule in combination with aspirin to prevent cerebral thromboembolism due to NVAF is safe and it does not need detecting INR. Tongxinluo capsule in combination with aspirin to prevent cerebral thromboembolism due to NVAF was effective and safety.